AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15566078 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K
Number of subjects: 29
Study 15566078 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparameter classification process
Number of subjects: 29
Study 15566078 — intervention group
Group type: EXPERIMENTAL
Intervention: OC/PYD, vitamin K/PYD, vitamin K/bAP profiles
Number of subjects: 29
Study 15566078 — intervention group
Group type: EXPERIMENTAL
Intervention: PYD and DPD
Number of subjects: 29
Study 15566078 — intervention group
Group type: EXPERIMENTAL
Intervention: Other biochemical markers (AP, bAP, OC, ucOC, PICP, NTX, BSP)
Number of subjects: 29
Study 12396862 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Dysport)
Number of subjects: 18
Study 9564199 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall 5 mg
Number of subjects: 0
Study 9564199 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall 10 mg
Number of subjects: 0
Study 9564199 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall 15 mg
Number of subjects: 0
Study 9564199 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall 20 mg
Number of subjects: 0
Study 9564199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9564199 — intervention group
Group type: COMPARATOR
Intervention: Ritalin (active control)
Number of subjects: 0
Study 7811206 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maleic acid etched for 15 seconds (Group 1)
Number of subjects: 80
Study 7811206 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maleic acid etched for 30 seconds (Group 2)
Number of subjects: 80
Study 7811206 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid etched for 15 seconds (Group 3)
Number of subjects: 80
Study 7811206 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maleic acid etched for 15 seconds on primary teeth (Group 4)
Number of subjects: 80
Study 2841841 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g soy polysaccharide
Number of subjects: 0
Study 2841841 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g soy polysaccharide
Number of subjects: 0
Study 2841841 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g soy polysaccharide
Number of subjects: 0
Study 2841841 — intervention group
Group type: COMPARATOR
Intervention: Liquid-formula diet without soy polysaccharide
Number of subjects: 0
Study 29398452 — intervention group
Group type: EXPERIMENTAL
Intervention: Model and verbal instructions
Number of subjects: 30
Study 29398452 — intervention group
Group type: COMPARATOR
Intervention: Model only
Number of subjects: 30
Study 29782181 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic abdominal manual intervention (AMI)
Number of subjects: 62
Study 29782181 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 62
Study 27644566 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meals (HF group)
Number of subjects: 232
Study 27644566 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-kcal low-calorie density (CD) high-protein meal (HF group)
Number of subjects: 232
Study 27644566 — intervention group
Group type: COMPARATOR
Intervention: Normal meals (normal group)
Number of subjects: 232
Study 24503114 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg
Number of subjects: 25
Study 24503114 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 20 mg
Number of subjects: 25
Study 22525956 — intervention group
Group type: EXPERIMENTAL
Intervention: Molindone, Olanzapine, Risperidone
Number of subjects: 116
Study 19957683 — intervention group
Group type: EXPERIMENTAL
Intervention: WFG-LASIK
Number of subjects: 102
Study 19957683 — intervention group
Group type: COMPARATOR
Intervention: Conventional LASIK
Number of subjects: 102
Study 19957683 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK (both groups)
Number of subjects: 102
Study 17986035 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 141
Study 17986035 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20% bupivacaine
Number of subjects: 141
Study 17986035 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20% levobupivacaine
Number of subjects: 141
Study 17986035 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 141
Study 17986035 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% solutions
Number of subjects: 141
Study 17986035 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% solutions
Number of subjects: 141
Study 17986035 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 141
Study 15659490 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with cyclophosphamide, mitoxantrone, and etoposide followed by peripheral-blood stem-cell transplantation, repeated after 6 weeks.
Number of subjects: 93
Study 15659490 — intervention group
Group type: COMPARATOR
Intervention: Standard combination therapy with doxorubicin and paclitaxel (AT).
Number of subjects: 93
Study 11843986 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial Intervention Training (PSI) for 20 nurses over 6 months
Number of subjects: 33
Study 11843986 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (C)
Number of subjects: 33
Study 10194129 — intervention group
Group type: COMPARATOR
Intervention: T cell receptor (TCR) variable (V) region expression assessment using monoclonal antibodies specific for different V region families (alpha or beta) in combination with anti‐CD4 or anti‐CD8.
Number of subjects: 37
Study 10194129 — intervention group
Group type: COMPARATOR
Intervention: Expanded T cell subsets in MM patients (N=3) with larger percentages (34-84%) of these subsets within their blood T (CD3+) cells.
Number of subjects: 37
Study 10194129 — intervention group
Group type: COMPARATOR
Intervention: Assessment of T cell repertoire in newly diagnosed, untreated MM patients (N=13).
Number of subjects: 37
Study 7749881 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 2.5 mg
Number of subjects: 81
Study 7749881 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 mg
Number of subjects: 81
Study 7749881 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 81
Study 7749881 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 81
Study 7749881 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 81
Study 7749881 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 81
Study 7749881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 2135210 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms) + Fenoterol (400 micrograms)
Number of subjects: 48
Study 2135210 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms)
Number of subjects: 48
Study 2135210 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (400 micrograms)
Number of subjects: 48
Study 2135210 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms) + Fenoterol (200 micrograms or more)
Number of subjects: 48
Study 380736 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg metronidazole as an intravenous infusion during the operation
Number of subjects: 100
Study 380736 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 100
Study 6760867 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 10
Study 6760867 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen
Number of subjects: 10
Study 30771560 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase standing intervention
Number of subjects: 250
Study 30771560 — intervention group
Group type: COMPARATOR
Intervention: Heart healthy attention-comparison condition
Number of subjects: 250
Study 29101708 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT with dose of 15 J per site
Number of subjects: 18
Study 29101708 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT with doses of 30 J per site
Number of subjects: 18
Study 29101708 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT with doses of 60 J per site
Number of subjects: 18
Study 29101708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29101708 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 24446755 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 sessions of NB‐UVB treatment before transplantation
Number of subjects: 437
Study 24446755 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 sessions of NB‐UVB treatment after transplantation
Number of subjects: 437
Study 24446755 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 sessions of NB‐UVB treatment before transplantation and 30 sessions after transplantation
Number of subjects: 437
Study 24446755 — intervention group
Group type: COMPARATOR
Intervention: Only transplantation (no NB‐UVB treatment)
Number of subjects: 437
Study 22055478 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition supplemented with L-glutamine (30 g) for 2 days
Number of subjects: 30
Study 22055478 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition with calcium caseinate (30 g) for 2 days
Number of subjects: 30
Study 22055478 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition supplemented with L-glutamine (30 g) followed by calcium caseinate (30 g)
Number of subjects: 30
Study 22055478 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition with calcium caseinate (30 g) followed by L-glutamine (30 g)
Number of subjects: 30
Study 19345944 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of oral mifepristone followed 48 hours later with 400 microg of oral misoprostol, administered either at home or at the clinic
Number of subjects: 400
Study 19345944 — intervention group
Group type: EXPERIMENTAL
Intervention: Home administration of misoprostol
Number of subjects: 400
Study 17848325 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopic resection with a 26F resectoscope with unipolar knife (group A)
Number of subjects: 160
Study 17848325 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-diameter hysteroscopy with Versapoint device (group B)
Number of subjects: 160
Study 15482522 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam-cooked kiwifruit (100 degrees C for 5 minutes)
Number of subjects: 20
Study 15482522 — intervention group
Group type: COMPARATOR
Intervention: Homogenised kiwifruit preparation
Number of subjects: 20
Study 15482522 — intervention group
Group type: COMPARATOR
Intervention: Fresh kiwifruit
Number of subjects: 20
Study 11864944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g administered every 12 hours
Number of subjects: 0
Study 10732308 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA infants
Number of subjects: 317
Study 10732308 — intervention group
Group type: COMPARATOR
Intervention: AGA infants
Number of subjects: 317
Study 8657964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole (1 g i.v.)
Number of subjects: 100
Study 8657964 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal metronidazole (1 g suppository)
Number of subjects: 100
Study 8657964 — intervention group
Group type: COMPARATOR
Intervention: Control group (gentamycin 80 mg i.v. + metronidazole 1 g i.v. or suppository)
Number of subjects: 100
Study 8657964 — intervention group
Group type: COMPARATOR
Intervention: Postoperative observation
Number of subjects: 100
Study 2158192 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus extract, administered orally for 1 month
Number of subjects: 0
Study 2158192 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus extract, administered intraperitoneally (i.p.)
Number of subjects: 0
Study 6451235 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg daily)
Number of subjects: 2
Study 6451235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (500 mg twice daily)
Number of subjects: 2
Study 6451235 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 2
Study 29889599 — intervention group
Group type: EXPERIMENTAL
Intervention: MT plus TPE based on a biobehavioral approach and therapeutic exercise (Exp2)
Number of subjects: 47
Study 29889599 — intervention group
Group type: EXPERIMENTAL
Intervention: MT plus TPE based on a biobehavioral approach (Exp1)
Number of subjects: 47
Study 29889599 — intervention group
Group type: COMPARATOR
Intervention: MT (control group)
Number of subjects: 47
Study 30819520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (120 mg)
Number of subjects: 154
Study 30819520 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydromorphone (1 mg)
Number of subjects: 154
Study 30819520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (120 mg) in patients with nephrolithiasis
Number of subjects: 154
Study 30819520 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydromorphone (1 mg) in patients with nephrolithiasis
Number of subjects: 154
Study 28724183 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-Inositol-based supplement (Folandrol®, Exeltis, Hungary) for two months and semen incubation with 2 mg/ml of Myo-Inositol for 2 hours before PICSI procedures.
Number of subjects: 0
Study 28724183 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment during the same time range).
Number of subjects: 0
Study 24899241 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality distraction
Number of subjects: 98
Study 24899241 — intervention group
Group type: COMPARATOR
Intervention: Control group (no virtual reality distraction)
Number of subjects: 98
Study 23662639 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligent virtual reality (VR)‐based vocational problem‐solving skill training programme
Number of subjects: 40
Study 23662639 — intervention group
Group type: COMPARATOR
Intervention: Conventional psycho‐educational approach
Number of subjects: 40
Study 21195257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 24
Study 21195257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21195257 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 24
Study 21195257 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 24
Study 19943918 — intervention group
Group type: EXPERIMENTAL
Intervention: Best supportive nutritional care (BSNC) plus parenteral nutrition (PN)
Number of subjects: 120
Study 19943918 — intervention group
Group type: COMPARATOR
Intervention: Best supportive nutritional care (BSNC)
Number of subjects: 120
Study 17299067 — intervention group
Group type: EXPERIMENTAL
Intervention: l-T(4) (1.3 microg/kg daily) for 24 months
Number of subjects: 30
Study 17299067 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 30
Study 14722177 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 76
Study 14722177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 76
Study 14722177 — intervention group
Group type: COMPARATOR
Intervention: Control (CLMA)
Number of subjects: 76
Study 14722177 — intervention group
Group type: COMPARATOR
Intervention: Control (PLMA)
Number of subjects: 76
Study 12370553 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based exercise training (Hosp)
Number of subjects: 242
Study 12370553 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training (Home)
Number of subjects: 242
Study 10435233 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite cancer control intervention
Number of subjects: 111
Study 10435233 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study 7752912 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-g fructose solution with 300 mg caffeine
Number of subjects: 16
Study 7752912 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-g glucose solution with 300 mg caffeine
Number of subjects: 16
Study 7752912 — intervention group
Group type: COMPARATOR
Intervention: 75-g fructose solution without caffeine (placebo)
Number of subjects: 16
Study 7752912 — intervention group
Group type: COMPARATOR
Intervention: 75-g glucose solution without caffeine (placebo)
Number of subjects: 16
Study 2306439 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aqueous indomethacin one hour beforehand
Number of subjects: 114
Study 2306439 — intervention group
Group type: COMPARATOR
Intervention: No treatment (comparison group)
Number of subjects: 114
Study 7002355 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg twice daily)
Number of subjects: 0
Study 7002355 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg four times daily)
Number of subjects: 0
Study 7002355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (200 mg four times daily)
Number of subjects: 0
Study 7002355 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus Sulfinpyrazone
Number of subjects: 0
Study 7002355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29393162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec Plus®
Number of subjects: 32
Study 29393162 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 32
Study 26324180 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) for 16 weeks
Number of subjects: 11
Study 26324180 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 matched subjects, BMI = 34 kg/m²)
Number of subjects: 11
Study 24811386 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-state fMRI data analysis
Number of subjects: 1147
Study 22314425 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5885 1 mg QD
Number of subjects: 60
Study 22314425 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5885 3 mg QD
Number of subjects: 60
Study 22314425 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5885 10 mg QD
Number of subjects: 60
Study 22314425 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5885 30 mg QD
Number of subjects: 60
Study 22314425 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-5885 90 mg QD
Number of subjects: 60
Study 22314425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20358265 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing‐Single Session (MI‐Single)
Number of subjects: 256
Study 20358265 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing‐Group (MI‐Group)
Number of subjects: 256
Study 20358265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse‐Led Hepatitis Health Promotion (HHP)
Number of subjects: 256
Study 20358265 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 256
Study 18379010 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-color flow cytometry
Number of subjects: 98
Study 18379010 — intervention group
Group type: COMPARATOR
Intervention: Polymerase chain reaction
Number of subjects: 98
Study 16129384 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine treatment
Number of subjects: 0
Study 12162601 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 h cyclical lighting (intensity of light: 78.4 +/‐ 24.7 lux)
Number of subjects: 96
Study 12162601 — intervention group
Group type: COMPARATOR
Intervention: Continuously dim environment (5.9 +/‐ 1.9 lux)
Number of subjects: 96
Study 12162601 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 h cyclical lighting
Number of subjects: 96
Study 12162601 — intervention group
Group type: COMPARATOR
Intervention: Continuously dim environment
Number of subjects: 96
Study 10782903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 14-16 mg/kg/day
Number of subjects: 192
Study 10782903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 10782903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 192
Study 8903001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (30 mg; i.m.)
Number of subjects: 12
Study 8903001 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone (1.0 g; 2.5 g; i.v.)
Number of subjects: 12
Study 1853794 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic treatment
Number of subjects: 53
Study 1853794 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose antibiotic treatment
Number of subjects: 53
Study 6191994 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (40 micrograms kg‐1 h‐1, i.v.)
Number of subjects: 10
Study 6191994 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg)
Number of subjects: 10
Study 6191994 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10
Study 6191994 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 10
Study 30590537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 300 mcg/kg/day
Number of subjects: 141
Study 30590537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 600 mcg/kg/day
Number of subjects: 141
Study 30590537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 29793404 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment for GDM
Number of subjects: 4000
Study 29793404 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 4000
Study 26871879 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 151
Study 26871879 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 151
Study 24725909 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable bare-metal stents (BMSs)
Number of subjects: 162
Study 24725909 — intervention group
Group type: COMPARATOR
Intervention: Covered balloon-expandable stents (CBE)
Number of subjects: 162
Study 22433473 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide (520 mg/day of elemental magnesium)
Number of subjects: 41
Study 22433473 — intervention group
Group type: COMPARATOR
Intervention: Magnesium citrate (295.8 mg/day of elemental magnesium)
Number of subjects: 41
Study 20060161 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg misoprostol
Number of subjects: 978
Study 20060161 — intervention group
Group type: COMPARATOR
Intervention: 40 IU intravenous oxytocin
Number of subjects: 978